170439 ⎘
Assays involving biological materials from specific organisms or of a specific nature from animals; from humans; Assays involving cytokines Interferons [IFN]
Sub-classes:METHOD FOR SCREENING AND PREPARING IMMUNOMODULATOR
#2PEPTIDE COMPOSITION AND USES THEREOF
#3PROTEIN SIGNATURES FOR DISTINGUISHING BETWEEN BACTERIAL AND VIRAL INFECTIONS
#4METHODS AND COMPOSITIONS FOR T-CELL COCULTURE POTENCY ASSAYS AND USE WITH CELL THERAPY PRODUCTS
#5IMMUNOMODULATORY CLINICAL BIOMARKER PROFILES AND USES THEREOF
#6SIMULATED SYNOVIAL FLUIDS FOR MODELING DEGENERATIVE JOINT DISEASES AND SCREENING FOR THERAPEUTICS FOR SAME
#7Type 1 IFN Assays and Methods of Diagnosis for Susceptibility to and Treatment of Viral Disease and Viral Vaccines, Including Covid -19
#8Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
#9PREDICTION AND EARLY DIAGNOSIS OF ACUTE KIDNEY INJURY
#10Protein signatures for distinguishing between bacterial and viral infections
#11METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS
#12PEPTIDE COMPOSITION AND USES THEREOF
#13COMPOSITIONS AND METHODS FOR EVALUATING POTENCY OF LISTERIA-BASED IMMUNOTHERAPEUTICS
#14SURFACE FUNCTIONALISED MATERIALS FOR SAMPLING BIOLOGICAL MOLECULES
#15Yeast-based immunotherapy and type I interferon sensitivity
#16Safe and effective method of treating lupus with anti-IL12/IL23 antibody
#17Protein signatures for distinguishing between bacterial and viral infections
#18BIOMARKERS
#19Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers
#20Biomarkers for assessing risk of transitioning to systemic lupus erythematosus classification and disease pathogenesis
#21Methods for increasing levels of interferon activity with an interferon lambda 3 polypeptide
#22Yeast-based immunotherapy and type I interferon sensitivity
#23METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS
#24Method for increasing interferon activity in an individual
#25ANTI-ILT7 ANTIBODY
#26Nanoelectronic-enzyme linked immunosorbent assay system and method
#27Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer
#28Biomarkers
#29Method for monitoring HIV specific T cell responses
#30Biomarker panel for detecting lung cancer
#31Multiple interferon and virus response element cell-based fluorescence system
#32PROCESS FOR THE MEASUREMENT OF THE POTENCY OF GLATIRAMER ACETATE
#33METHODS FOR DIAGNOSIS OF IMMUNE RESPONSES AGAINST VIRUSES
#34Anti-ILT7 antibody
#35Interferon-lambda 1 polypeptides
#36METHODS OF PREDICTING RESPONSIVENESS TO INTERFERON TREATMENT AND TREATING HEPATITIS C INFECTION
#37BIOMARKERS FOR PREDICTING SUSTAINED RESPONSE TO HCV TREATMENT
#38Process for the measurement of the potency of glatiramer acetate
#39IFN-ALPHA/BETA-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION THROUGH A NOVEL LIGAND-RECEPTOR PAIR: IFN- LIGANDS ENGAGE A NOVEL RECEPTOR IFN-RN (CRF2-12) AND IL-10R2 (CRF2-4) FOR SIGNALING ANDINDUCTION OF BIOLOGICAL ACTIVITIES
#40CELL-BASED SCREENING ASSAY TO IDENTIFY MOLECULES THAT STIMULATE IFN-ALPHA/BETA TARGET GENES
#41INTERFERON EPSILON (IFNE1) AS A MARKER FOR TARGETED CANCER THERAPY
#42Biomarker
#43IL-18 and Protein Kinase R Inhibition for the Treatment of COPD
#44Nanoelectronic-enzyme linked immunosorbent assay system and method
#45SINGLE MOLECULE ASSAYS
#46Anti-ILT7 antibody
#47IFN-λ polypeptides and compositions
#48Process for the measurement of the potency of glatiramer acetate
#49Diagnostic marker for interferon responsiveness in multiple sclerosis
#50UbcH8 Ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an interferon alpha/beta induced Ubiquitin-like protein
#51Screening for gestational disorders
#52Method of using physiological markers to estimate cardiovascular risk
#53Compositions and methods for treatment of central nervous system (CNS) autoimmune associated diseases or disorders